You can buy or sell ALDX and other stocks, options, ETFs, and crypto commission-free!
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. Read More The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
52 Week High
52 Week Low
Simply Wall St13h
Can You Imagine How Aldeyra Therapeutics’s (NASDAQ:ALDX) Shareholders Feel About The 68% Share Price Increase?
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shareholders might be concerned after seeing the share price drop 14% in the last week. But that shouldn’t obscure the pleasing returns achieved by shareholders over the last three years. In fact, the company’s share price bested the return of its market index in that time, posting a gain of 68%. Check out our latest analysis for Aldeyra Therapeutics With zero revenue generated over twelve months, we don’t think that Aldeyra Therapeutics has proved its business pla...
Aldeyra's Eye Inflammation Drug Aces Late-Stage Trial, Stock Rises 60% (NASDAQ:ALDX)
Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are advancing strongly Tuesday following the release of the results of a late-stage study of its drug candidate for allergic conjunctivitis.
Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints
Shares of Aldeyra Therapeutics Inc. ALDX, -4.16% shot up 56% toward a 5-month high in premarket trade Tuesday, a day after closing at a 7-month low, after a phase 3 trial of the biotechnology company's allergic conjunctivitis treatment met its primary and secondary endpoints. Trading volume topped 440,000 shares, already more than the full-day average of about 310,000 shares. Aldeyra said it plans to meet with regulatory authorities in the second half of 2019 to discuss the results and remaining clinical re...
Expected May 14, Pre-Market